Buried Barrett's epithelium following photodynamic therapy shows reduced crypt proliferation and absence of DNA content abnormalities
- PMID: 18076737
- DOI: 10.1111/j.1572-0241.2007.01560.x
Buried Barrett's epithelium following photodynamic therapy shows reduced crypt proliferation and absence of DNA content abnormalities
Abstract
Objectives: Photodynamic therapy (PDT) is increasingly used for the treatment of patients with Barrett's esophagus (BE) with dysplasia or early carcinoma. Post-PDT, some patients show residual BE either exposed to the luminal surface (nonburied) or buried underneath reepithelialized squamous mucosa (buried BE). Buried BE may be a serious clinical problem since it can go unnoticed during surveillance endoscopies. The neoplastic potential of buried BE is poorly understood. The aim of this study was to evaluate the biological characteristics of nonburied and buried BE in patients treated with PDT.
Methods: Twelve patients selected from a cohort of 52 BE patients who received PDT for high-grade dysplasia or intramucosal adenocarcinoma were used for this study because they all had both pre- and post-PDT (nonburied), and post-PDT buried, BE biopsies, without dysplasia, available for analysis. The biopsies were immunostained for Ki-67, p53, cyclin D1, bcl-2, TGF-alpha, EGFR, and AMACR. High fidelity DNA histograms were obtained by image cytometry analysis of Feulgen stained slides, and used to determine peak DNA index (DI), DNA heterogeneity, and 5N exceeding rate (5NER). Comparisons were made between pre-PDT nonburied BE and post-PDT nonburied and buried BE.
Results: Pre-PDT BE showed an elevated Ki-67 crypt proliferation rate (43.3%) and p53, bcl-2, TGF-alpha, and EGFR positivity in 8%, 25%, 75%, and 25% of cases, respectively. Cyclin D1 and AMACR were negative in all cases. High fidelity DNA histograms showed mild aneuploidy in 73% of cases. Post-PDT buried BE showed a significantly lower Ki-67 crypt proliferation rate (29.9%) in comparison to nonburied BE, in both pre- PDT (43.3%) and post-PDT (44.4%) biopsies (P < 0.05), but similar rates of positivity for the other peptide markers. In contrast to pre-PDT nonburied BE biopsies, high fidelity DNA histograms revealed that none of the buried BE (0%), and only 2/9 (11%) nonburied BE post-PDT, showed aneuploidy.
Conclusions: Pre-PDT nonburied BE, without dysplasia, shows elevated crypt proliferation and mild, but frequent, DNA content abnormalities. Post-PDT, nonburied BE shows persistently elevated crypt proliferation, but significantly less frequent DNA content abnormalities, whereas buried BE shows decreased crypt proliferation and normal DNA content profile. These results suggest that post-PDT buried BE may have a lower neoplastic potential than pre-PDT BE.
Similar articles
-
Buried dysplasia and early adenocarcinoma arising in barrett esophagus after porfimer-photodynamic therapy.Am J Surg Pathol. 2007 Mar;31(3):403-9. doi: 10.1097/01.pas.0000213407.03064.37. Am J Surg Pathol. 2007. PMID: 17325482
-
Photodynamic therapy (PDT) in Barrett's esophagus with dysplasia or early cancer.Eur J Cardiothorac Surg. 2006 Jan;29(1):30-4. doi: 10.1016/j.ejcts.2005.10.033. Epub 2005 Dec 6. Eur J Cardiothorac Surg. 2006. PMID: 16337389
-
Advanced pathology under squamous epithelium on initial EMR specimens in patients with Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma: implications for surveillance and endotherapy management.Gastrointest Endosc. 2009 Sep;70(3):417-21. doi: 10.1016/j.gie.2009.01.047. Epub 2009 Jun 24. Gastrointest Endosc. 2009. PMID: 19555948
-
[Flow cytometric analysis of cellular DNA content in Barret's esophagus. A study of 66 cases].Gastroenterol Clin Biol. 1991;15(10):703-10. Gastroenterol Clin Biol. 1991. PMID: 1816011 Review. French.
-
Laser ablation therapies for Barrett's esophagus.Semin Thorac Cardiovasc Surg. 2005 Winter;17(4):313-9. doi: 10.1053/j.semtcvs.2005.10.004. Semin Thorac Cardiovasc Surg. 2005. PMID: 16428037 Review.
Cited by
-
Barrett's Esophagus: A Comprehensive and Contemporary Review for Pathologists.Am J Surg Pathol. 2016 May;40(5):e45-66. doi: 10.1097/PAS.0000000000000598. Am J Surg Pathol. 2016. PMID: 26813745 Free PMC article. Review.
-
Prevalence and predictors of recurrent neoplasia after ablation of Barrett's esophagus.Gastrointest Endosc. 2010 Apr;71(4):697-703. doi: 10.1016/j.gie.2009.08.031. Epub 2009 Dec 3. Gastrointest Endosc. 2010. PMID: 19959164 Free PMC article.
-
Buried metaplasia after endoscopic ablation of Barrett's esophagus: a systematic review.Am J Gastroenterol. 2011 Nov;106(11):1899-908; quiz 1909. doi: 10.1038/ajg.2011.255. Epub 2011 Aug 9. Am J Gastroenterol. 2011. PMID: 21826111 Free PMC article.
-
Managing Barrett's esophagus with radiofrequency ablation.Gastroenterol Rep (Oxf). 2013 Sep;1(2):95-104. doi: 10.1093/gastro/got009. Epub 2013 Mar 26. Gastroenterol Rep (Oxf). 2013. PMID: 24759814 Free PMC article.
-
Comparison of COX-2, Ki-67, and BCL-2 expression in normal esophageal mucosa, Barrett's esophagus, dysplasia, and adenocarcinoma with postablation mucosa and implications for ablative therapies.Surg Endosc. 2011 Aug;25(8):2564-9. doi: 10.1007/s00464-011-1587-3. Epub 2011 Feb 27. Surg Endosc. 2011. PMID: 21359892
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous